Abstract

Zoetis will report fiscal Q2 2026 results on August 06, 2026 Pre-Market.

Market Forecast

Consensus compiled from current quarter forecasts points to revenue of 2.50 billion US dollars, EBIT of 1.03 billion US dollars, and adjusted EPS of 1.86; year over year, these imply growth of 3.87% for revenue, 7.94% for EBIT, and 14.74% for adjusted EPS. Company-level margin forecasts are not explicitly guided, but the market expects stability to modest expansion; last quarter’s gross margin was 71.71% and net profit margin was 26.57%. The main business profile remains diversified, led by parasiticides and vaccines, with dermatology and anti-infectives as meaningful contributors. The most promising near-term growth driver is dermatology, with quarterly revenue of 349.00 million US dollars; growth outlook is supported by sustained uptake in companion animal therapeutics.

Last Quarter Review

Zoetis reported last quarter revenue of 2.26 billion US dollars, a gross profit margin of 71.71%, GAAP net profit attributable to the parent company of 601.00 million US dollars, a net profit margin of 26.57%, and adjusted EPS of 1.53, representing year-over-year growth of 1.89% for revenue and 3.38% for adjusted EPS. A notable financial highlight was EBIT of 860.00 million US dollars, which was below consensus and reflected a 2.61% year-over-year decline, while adjusted EPS also came in below expectations. Main business highlights: parasiticides generated 586.00 million US dollars, vaccines 519.00 million US dollars, dermatology 349.00 million US dollars, anti-infectives 241.00 million US dollars, and pain and sedation 203.00 million US dollars.

Current Quarter Outlook

Main commercial engine: Parasiticides and vaccines

Parasiticides and vaccines remain the core revenue pillars this quarter, together accounting for roughly half of group sales in the last reported period. For Q2 2026, resilience in these categories is expected to underpin the topline given steady demand across companion and livestock portfolios and continued product innovation cycles. While seasonal patterns can influence ordering, market checks suggest sell-through has held up, and stable pricing dynamics should support gross margin continuity given the last quarter’s 71.71% level. A modest revenue growth forecast of 3.87% aligns with an environment of steady volume contribution from these mature, high-penetration franchises, limiting downside volatility even as mix shifts toward higher-value therapeutics.

Most promising business: Dermatology therapeutics

Dermatology has emerged as a leading growth vector, with last quarter revenue of 349.00 million US dollars and strong underlying demand for companion-animal dermatology treatments. The forecasted acceleration in adjusted EPS to 1.86, up 14.74% year over year, implies operating leverage that is consistent with continued adoption of dermatology products. As mix tilts toward specialty therapeutics, incremental gross profit contribution can exceed company average, sustaining EBIT expansion of 7.94% year over year to 1.03 billion US dollars. Inventory normalization and field execution should be watched, but current indicators suggest momentum remains intact heading into the print.

Key stock-price swing factors this quarter

The first swing factor is margin trajectory relative to last quarter’s 71.71% gross margin and 26.57% net margin; any deviation will disproportionately influence EPS given the forecast 3.87% revenue growth base. The second factor is the performance of dermatology and parasiticides versus expectations; upside in these segments could enable outperformance on EBIT and EPS, while shortfalls may compress operating leverage. The third factor is management’s commentary on full-year guidance and demand cadence across companion versus livestock end-markets, which can recalibrate investor expectations for the back half. Together, these dynamics frame a setup where modest topline growth paired with disciplined cost control can still deliver double-digit EPS growth.

Analyst Opinions

Most recent analyst commentary over the past six months has leaned bullish, with the majority highlighting durable demand in companion-animal therapeutics and the potential for margin stability to lift earnings quality. Several well-followed institutions expect Zoetis to show improving growth composition as dermatology expands its share of revenue, supporting the view that adjusted EPS can grow faster than sales in the near term. Analysts also point to a manageable comparison base after last quarter’s modest miss, suggesting room for positive surprise if inventory and channel dynamics in key categories normalize as anticipated. Overall, the majority outlook emphasizes steady revenue growth near 3.87% and improving operating leverage driving EPS toward 1.86, with attention centered on mix improvements in parasiticides and dermatology.